Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer - Wikidata - wikimedia - TriplyDB

Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer

Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer

http://www.wikidata.org/entity/Q35064835

about

The variable phenotype and low-risk nature of RAS-positive thyroid nodules.RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer.Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making.Diagnostic Value of RAS Mutations in Indeterminate Thyroid Nodules.The role of molecular diagnostic testing in the management of thyroid nodules.Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit.Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.Benign thyroid nodules with RAS mutation grow faster.BRAF 1799T>A Mutation Frequency in Mexican Mestizo Patients with Papillary Thyroid Cancer.Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.Evaluation of the Role of V600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates

P2860

Q35740151-0821153F-499C-4724-9E40-1CC7D2186EE6 Q35858147-878FA40E-1A5A-4A11-955B-9D71B69078AF Q35935584-9F48B484-F348-4AB8-8E39-5D7949909FF5 Q36139842-07F9F05F-E9BE-461A-89C8-B268EA042FB6 Q36360429-D12E994D-B4B3-4E15-A7A8-7C533D2B8E75 Q37616582-1FC6927B-479F-4A8A-8ABC-FC56A01A3C46 Q39002659-E0C761BA-39B3-490B-B76C-FA9E1D046BE8 Q39250953-80D4426D-5E47-4786-93F8-5EC3DC66381C Q39395238-1E757B24-60FE-408D-8A2A-7EC8765AFE82 Q41665358-7F127C27-C9E2-496C-812B-F748ADA25CE1 Q42014310-F02F2789-4AFB-4EA9-A5BE-F80971225AAA Q47094119-89D5913C-59FE-4619-95E4-60798FB3DA91 Q47123875-B01BFAF0-B46F-4E38-97A5-09DA87B2011A Q50043138-9C39600E-4BEE-4417-8FD7-975F58FEC1EE Q51286115-E438A00F-2B05-404A-BDFB-1459AC78F156 Q54964968-A3C671DB-82E5-426C-AB7E-E291DFDB1962 Q54967888-697630CF-4F59-4975-9068-3072C80DAA0B Q54977969-5F8179C5-3B23-418D-8905-443F3534CD62 Q58124607-1B439108-A693-4A04-8A23-F3A6BC53C844 Q58796314-C9F7B02C-6A81-4411-80A7-40AB4978C6AA

P2860

Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer

http://www.wikidata.org/entity/Q35064835

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@ast

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@en

type

label

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@ast

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@en

prefLabel

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@ast

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@en

P1433

Q35064835-863370D3-67AC-45EA-B21F-24C3F249C79B

P1476

Q35064835-23EDEB35-5003-47CC-8AD4-98BF30A9D55D

P2093

Q35064835-36B7729C-CDE1-4E8C-B0C2-45890847C6A1

Q35064835-43231980-E411-4135-AD19-607C32D95F8A

Q35064835-453EBC45-A813-4949-B804-E7F9B9273C8A

Q35064835-4555EF13-7885-4848-83C0-631E1392E437

Q35064835-46DDEBEA-0A03-4BE2-BF4B-311A87E815ED

Q35064835-69C9DF8A-8913-4FA7-8E84-F39AC59A225F

Q35064835-CCBDB7FA-8827-4BC2-BDA2-DD7B9E65BABD

Q35064835-F5B26130-F7E5-4FCA-8534-1B396041BBBB

P2860

Q35064835-088E807D-35E9-4E51-90F4-36523AE88491

Q35064835-09288D66-1A8E-4E44-8D25-99FE3B8A8EC8

Q35064835-11E03438-2C74-4752-965B-EACB0647C75A

Q35064835-14157B08-007E-4520-B337-6B9C6D36336D

Q35064835-1D00F34D-E2D3-4A73-B75E-49F3E538171B

Q35064835-343086A1-01A3-4DC6-ADC5-24D67459C637

Q35064835-40E05D07-ADCD-4C0E-AFA4-E63CC6CC2BDE

Q35064835-436D013E-10B9-42A0-8885-30B3C3B3271D

Q35064835-4BDB1DB7-8877-489C-AC3E-0E9FE9A95B15

Q35064835-564888AF-A0F6-4F73-9E98-6A58D577DC05

P304

Q35064835-A6CEBCDE-0993-45C8-B1C0-40B2E0232337

P31

Q35064835-582B006E-1D46-4EE7-917B-3BDC0DF53FD2

P356

Q35064835-D30AD0BE-9B8C-47F3-9A83-8242675D0C6D

P433

Q35064835-90ECAEA4-71DF-41BB-80F9-7BCD3FBC2588

P478

Q35064835-535EEE6C-404B-4A96-8B60-9261C5A5456B

P50

Q35064835-69705685-1F2C-4762-A743-499376CEDB1C

Q35064835-E08F0A49-4515-4148-B626-8C50D6D993E0

Q35064835-F99D3B71-7529-408A-B779-1BA0D2C73C46

P577

Q35064835-DB19D1B9-F037-4970-8BAA-E2D62A5F2368

P698

Q35064835-B1C4244B-2EF7-4473-B3C7-FA8EEC11F096

P932

Q35064835-5DDBB976-B32F-42A1-A669-BAA00567E18C

P356

P1433

P1476

Relevance of BRAF(V600E) mutat ...... he diagnosis of thyroid cancer

@en

P2093

Federico Tagliati

http://www.w3.org/2001/XMLSchema#string

Giorgio Trasforini

http://www.w3.org/2001/XMLSchema#string

Giovanni Lanza

http://www.w3.org/2001/XMLSchema#string

Martina Rossi

http://www.w3.org/2001/XMLSchema#string

Mattia Buratto

http://www.w3.org/2001/XMLSchema#string

Paola Franceschetti

http://www.w3.org/2001/XMLSchema#string

Roberta Rossi

http://www.w3.org/2001/XMLSchema#string

Stefania Bruni

http://www.w3.org/2001/XMLSchema#string

P2860

Progress in molecular-based management of differentiated thyroid cancer

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples

Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Thyroid papillary microcarcinoma: a descriptive and meta-analysis study.

Genetic markers differentiating follicular thyroid carcinoma from benign lesions.

Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.

Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules.

P304

221-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2014.0338

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Maria Chiara Zatelli

Ettore C degli Uberti

P577

2014-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25333496

http://www.w3.org/2001/XMLSchema#string

P932

4322031

http://www.w3.org/2001/XMLSchema#string